lncRNA PVT1 is significantly upregulated in non-small cell lung cancer.

PVT1 knockdown increased the number of lung cancer cells in the G0/G1 phase and reduced the number of cells in the S phase, while overexpression of PVT1 could promote cell cycle progression.

we found that PVT1 functioned as an oncogene and may be a crucial prognostic factor for NSCLC patients. PVT1 contributed to lung adenocarcinoma cell proliferation, partly though EZH2-medicated suppression of the LATS2/MDM2/P53 pathway.

LncRNA-PVT1 is a novel critical regulator in non-small cell lung cancer invasion.LncRNA-PVT1 regulates MMP9 expression.

High PVT1 expression is associated with lung cancer Progression.

Thus, our results indicated that lncRNA-PVT1-5 may function as a competing endogenous RNA (ceRNA) for miR-126 to promote cell proliferation by regulating the miR-126/SLC7A5 pathway, suggesting that lncRNA-PVT1-5 plays a crucial role in lung cancer progression and lncRNA-PVT1-5/miR-126/SLC7A5 regulatory network may shed light on tumorigenesis in lung cancer.

Knockdown of circular PVT1 inhibited non-small cell lung cancer cell proliferation.

A meta-analysis showed that high expression of PVT1 was significantly associated with tumor size, TNM stage, lymph node metastasis, distant metastasis, and overall survival time , especially in breast cancer, liver cancer and lung cancer.

CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p/ABCC1 axis.

The long non-coding RNA PVT1/miR-145-5p/ITGB8 axis regulates cell proliferation, apoptosis, migration and invasion in non-small cell lung cancer cells.

Clinical significance of circPVT1 in patients with non-small cell lung cancer who received cisplatin combined with gemcitabine chemotherapy.